Single-Cell/JJ
Sequencing/NN
in/IN
Cancer/NN
:/:
Recent/JJ
Applications/NNS
to/TO
Immunogenomics/NNS
and/CC
Multi-omics/NNS
Tools/NNS
./.
====================
Tumor/NN
heterogeneity/NN
,/,
the/DT
cellular/JJ
mosaic/JJ
of/IN
multiple/JJ
lineages/NNS
arising/VBG
from/IN
the/DT
process/NN
of/IN
clonal/JJ
evolution/NN
,/,
has/VBZ
continued/VBN
to/TO
thwart/VB
multi-omics/NNS
analyses/NNS
using/VBG
traditional/JJ
bulk/NN
sequencing/NN
methods/NNS
./.
====================
The/DT
application/NN
of/IN
single-cell/JJ
sequencing/NN
,/,
in/IN
concert/NN
with/IN
existing/VBG
genomics/NNS
methods/NNS
,/,
has/VBZ
enabled/VBN
high-resolution/JJ
interrogation/NN
of/IN
the/DT
genome/NN
,/,
transcriptome/VBP
,/,
epigenome/JJ
,/,
and/CC
proteome/VBP
./.
====================
Applied/VBN
to/TO
cancers/NNS
,/,
these/DT
single-cell/JJ
multi-omics/NNS
methods/NNS
bypass/VB
previous/JJ
limitations/NNS
on/IN
data/NNS
resolution/NN
and/CC
have/VBP
enabled/VBN
a/DT
more/RBR
nuanced/JJ
understanding/VBG
of/IN
the/DT
evolutionary/JJ
dynamics/NNS
of/IN
tumor/NN
progression/NN
,/,
immune/JJ
evasion/NN
,/,
metastasis/NN
,/,
and/CC
treatment/NN
resistance/NN
./.
====================
This/DT
review/NN
details/VBZ
the/DT
growing/VBG
number/NN
of/IN
novel/JJ
single-cell/JJ
multi-omics/NNS
methods/NNS
applied/VBN
to/TO
tumors/NNS
and/CC
further/RBR
discusses/VBZ
recent/JJ
discoveries/NNS
emerging/VBG
from/IN
these/DT
approaches/NNS
,/,
especially/RB
in/IN
regard/NN
to/TO
immunotherapy/NN
./.
====================
The/DT
advent/JJ
of/IN
genomic/JJ
medicine/NN
has/VBZ
bolstered/VBN
the/DT
appreciation/NN
of/IN
heterogeneity/NN
between/IN
and/CC
,/,
especially/RB
,/,
within/IN
tumors/NNS
./.
====================
This/DT
cellular/JJ
heterogeneity/NN
plays/VBZ
a/DT
major/JJ
role/NN
in/IN
tumor/NN
progression/NN
and/CC
sensitivity/NN
to/TO
anti-tumor/JJ
therapies/NNS
[/(
1/CD
,/,
2/CD
]/)
,/,
thereby/RB
posing/VBG
a/DT
significant/JJ
challenge/NN
to/TO
personalized/VBN
cancer/NN
therapy/NN
./.
====================
With/IN
continuing/VBG
advances/NNS
in/IN
high-throughput/JJ
single-cell/JJ
sequencing/NN
technology/NN
[/(
3/CD
,/,
4/CD
]/)
,/,
we/PRP
are/VBP
now/RB
able/JJ
to/TO
interrogate/VB
at/IN
high/JJ
resolution/NN
the/DT
genomic/JJ
features/NNS
of/IN
both/DT
the/DT
malignant/JJ
cells/NNS
and/CC
the/DT
immune/JJ
cells/NNS
residing/VBG
within/IN
the/DT
tumor/NN
microenvironment/NN
[/(
5â€“7/CD
]/)
to/TO
better/RBR
understand/VB
what/WP
promotes/VBZ
evasion/NN
from/IN
growth/NN
suppression/NN
and/CC
cell/NN
death/NN
signals/NNS
./.
====================
Given/IN
the/DT
extremely/RB
heterogenous/JJ
nature/NN
of/IN
tumors/NNS
and/CC
the/DT
equally/RB
diverse/JJ
immune/JJ
repertoire/NN
in/IN
a/DT
population/NN
,/,
single-cell/JJ
sequencing/NN
provides/VBZ
information/NN
that/IN
bulk/NN
sequencing/NN
can/MD
not/RB
,/,
such/JJ
as/IN
intratumoral/JJ
heterogeneity/NN
[/(
8/CD
,/,
9/CD
]/)
,/,
clonal/JJ
evolution/NN
[/(
4/CD
,/,
10/CD
,/,
11/CD
]/)
,/,
tumor/NN
microenvironment/NN
remodeling/VBG
status/NN
[/(
7/CD
,/,
12/CD
]/)
,/,
and/CC
development/NN
of/IN
cancer/NN
therapy/NN
resistance/NN
[/(
13/CD
]/)
./.
====================
This/DT
information/NN
will/MD
be/VB
invaluable/JJ
in/IN
the/DT
effort/NN
to/TO
predict/VB
targetable/JJ
mechanisms/NNS
of/IN
resistance/NN
to/TO
cancer/NN
immunotherapy/NN
,/,
a/DT
revolutionary/JJ
cancer/NN
treatment/NN
that/IN
harnesses/VBZ
the/DT
immune/JJ
system/NN
to/TO
battle/JJ
a/DT
wide/JJ
range/NN
of/IN
tumor/NN
types/NNS
including/VBG
melanoma/NN
,/,
renal/JJ
cell/NN
carcinoma/NN
,/,
and/CC
non-small/JJ
cell/NN
lung/NN
cancer/NN
[/(
14/CD
]/)
./.
====================
Understanding/VBG
tumor/NN
heterogeneity/NN
via/IN
single-cell/JJ
sequencing/NN
has/VBZ
implications/NNS
for/IN
the/DT
identification/NN
of/IN
biomarkers/NNS
for/IN
cancer/NN
and/CC
could/MD
help/VB
uncover/RB
approaches/NNS
to/TO
delay/VB
or/CC
reverse/JJ
acquired/VBN
resistance/NN
./.
====================
Multi-omics/NNS
is/VBZ
an/DT
umbrella/FW
term/NN
to/TO
describe/VB
multi-dimensional/JJ
analytical/JJ
methods/NNS
that/IN
integrate/VBP
high-throughput/RB
biomolecule/JJ
data/NNS
from/IN
multiple/JJ
sources/NNS
,/,
such/JJ
as/IN
the/DT
genome/NN
(/(
via/IN
whole/JJ
genome/NN
sequencing/VBG
)/)
,/,
transcriptome/DT
(/(
via/IN
RNA-Seq/JJ
)/)
,/,
proteome/DT
(/(
via/IN
liquid/JJ
chromatography/NN
with/IN
tandem/JJ
mass/NN
spectrometry/RB
)/)
,/,
interactome/DT
(/(
via/IN
genome-wide/JJ
chromosome/NN
conformation/NN
capture/JJ
[/(
Hi-C/JJ
]/)
)/)
,/,
epigenome/DT
(/(
via/IN
chromatin/NN
immunoprecipitation/NN
sequencing/VBG
[/(
ChIP-Seq/NNP
]/)
,/,
Bisulfite-Seq/NNP
,/,
or/CC
assay/NN
for/IN
transposase-accessible/JJ
chromatin/NN
using/VBG
sequencing/JJ
[/(
ATAC-Seq/JJ
]/)
)/)
,/,
and/CC
metabolome/JJ
(/(
via/IN
mass/JJ
spectrometry/RB
[/(
MS/NN
]/)
)/)
[/(
15/CD
]/)
./.
====================
Integration/NN
of/IN
multiple/JJ
biomolecular/JJ
datasets/NNS
is/VBZ
particularly/RB
relevant/JJ
to/TO
the/DT
investigation/NN
of/IN
factors/NNS
driving/VBG
tumorigenesis/NN
and/CC
metastasis/NN
since/IN
malignancy/NN
can/MD
arise/VB
from/IN
the/DT
concomitant/JJ
effects/NNS
of/IN
mild/JJ
perturbations/NNS
within/IN
interlinked/JJ
homeostatic/JJ
networks/NNS
that/IN
may/MD
individually/RB
go/VBP
unnoticed/JJ
[/(
16/CD
]/)
./.
====================
With/IN
the/DT
advent/JJ
of/IN
single-cell/JJ
sequencing/NN
approaches/NNS
,/,
multi-omics/NNS
methods/NNS
can/MD
be/VB
applied/VBN
to/TO
better/RBR
understand/VB
the/DT
complex/NN
interactions/NNS
and/CC
connections/NNS
in/IN
cell/NN
state/NN
and/CC
phenotype/NN
in/IN
the/DT
cancer/NN
ecosystem/VBP
and/CC
explore/VB
cellular/JJ
heterogeneity/NN
that/IN
often/RB
confounds/VBZ
biomolecular/JJ
variation/NN
from/IN
multi-omics/NNS
approaches/NNS
in/IN
bulk/NN
[/(
17/CD
]/)
./.
====================
This/DT
review/NN
presents/VBZ
the/DT
perspectives/NNS
of/IN
single-cell/JJ
genomic/JJ
analysis/NN
in/IN
cancer/NN
immunology/NN
,/,
the/DT
potential/JJ
pitfalls/NNS
of/IN
different/JJ
single-cell/JJ
analysis/NN
technology/NN
,/,
and/CC
the/DT
therapeutic/JJ
opportunity/NN
for/IN
cancer/NN
treatment/NN
as/IN
the/DT
hallmarks/NNS
of/IN
precision/NN
medicine/NN
in/IN
the/DT
future/JJ
./.
====================
A/DT
tumor/NN
is/VBZ
a/DT
complex/NN
ecosystem/NN
containing/VBG
an/DT
extensive/JJ
admixture/NN
of/IN
different/JJ
cell/NN
types/NNS
,/,
states/NNS
,/,
and/CC
fates/VBZ
./.
====================
Tumors/NNS
begin/NN
as/IN
a/DT
single/JJ
cell/NN
but/CC
,/,
during/IN
the/DT
process/NN
of/IN
tumor/NN
progression/NN
,/,
accumulate/VBP
somatic/JJ
mutations/NNS
and/CC
diversify/VBP
to/TO
form/VB
distinct/JJ
lineages/NNS
and/CC
subclonal/JJ
populations/NNS
./.
====================
This/DT
intratumor/NN
heterogeneity/NN
,/,
and/CC
the/DT
clonal/JJ
evolution/NN
that/DT
results/VBZ
,/,
plays/VBZ
a/DT
critical/JJ
role/NN
in/IN
many/JJ
processes/NNS
such/JJ
as/IN
immune/JJ
evasion/NN
,/,
angiogenesis/NN
,/,
and/CC
metastasis/NN
./.
====================
This/DT
heterogeneity/NN
poses/VBZ
a/DT
major/JJ
challenge/NN
for/IN
genomic/JJ
analysis/NN
by/IN
conventional/JJ
bulk/NN
sequencing/NN
which/WDT
typically/RB
measures/NNS
the/DT
average/NN
signal/NN
from/IN
an/DT
ensemble/JJ
of/IN
cells/NNS
and/CC
is/VBZ
thus/RB
a/DT
confounding/VBG
factor/NN
in/IN
clinical/JJ
diagnosis/NN
and/CC
therapeutic/JJ
treatment/NN
of/IN
patients/NNS
./.
====================
Understanding/VBG
genomic/JJ
alterations/NNS
at/IN
single-cell/JJ
resolution/NN
allows/VBZ
the/DT
accurate/JJ
identification/NN
of/IN
clonal/JJ
lineages/NNS
that/WDT
favored/VBD
proliferation/NN
despite/IN
treatment/NN
./.
====================
To/TO
date/NN
,/,
most/JJS
single-cell/JJ
DNA/NN
sequencing/NN
(/(
scDNA-Seq/NN
)/)
studies/NNS
of/IN
cancer/NN
have/VBP
focused/VBN
on/IN
intratumor/NN
heterogeneity/NN
and/CC
clonal/JJ
evolution/NN
in/IN
primary/JJ
tumors/NNS
./.
====================
One/CD
of/IN
the/DT
first/JJ
studies/NNS
to/TO
use/VB
scDNA-Seq/NN
to/TO
examine/VB
aneuploidy/NN
evolution/NN
in/IN
individual/JJ
cells/NNS
from/IN
triple-negative/JJ
breast/NN
cancer/NN
patients/NNS
found/VBD
punctuated/VBN
copy/NN
number/NN
evolution/NN
that/DT
was/VBD
followed/VBN
by/IN
stable/JJ
clonal/JJ
expansion/NN
[/(
18/CD
]/)
./.
====================
More/RBR
recently/RB
,/,
a/DT
study/NN
investigated/VBD
the/DT
genomic/JJ
evolution/NN
of/IN
single/JJ
cells/NNS
in/IN
triple-negative/JJ
breast/NN
cancer/NN
patients/NNS
who/WP
were/VBD
treated/VBN
with/IN
chemotherapy/NN
and/CC
found/VBD
two/CD
distinct/JJ
subclonal/JJ
populations/NNS
that/IN
were/VBD
undergoing/VBG
extinction/NN
and/CC
persistence/NN
[/(
19/CD
]/)
./.
====================
Among/IN
the/DT
many/JJ
single-cell/JJ
sequencing/NN
approaches/NNS
,/,
single-cell/JJ
RNA/NN
sequencing/NN
(/(
scRNA-Seq/NN
)/)
has/VBZ
been/VBN
the/DT
most/JJS
widely/RB
used/VBN
technique/NN
and/CC
has/VBZ
been/VBN
demonstrated/VBN
to/TO
be/VB
both/DT
accurate/JJ
and/CC
scalable/JJ
./.
====================
As/IN
a/DT
result/NN
,/,
scRNA-Seq/NN
has/VBZ
already/RB
had/VBD
a/DT
great/JJ
impact/NN
on/IN
improving/VBG
our/PRP$
fundamental/JJ
understanding/VBG
of/IN
intratumor/JJ
heterogeneity/NN
[/(
8/CD
,/,
9/CD
,/,
20/CD
,/,
21/CD
]/)
,/,
clonal/JJ
evolution/NN
[/(
10/CD
,/,
19/CD
,/,
21/CD
]/)
,/,
and/CC
metastatic/JJ
dissemination/NN
[/(
21/CD
]/)
in/IN
tumors/NNS
./.
====================
Previously/RB
,/,
application/NN
of/IN
scRNA-Seq/NN
was/VBD
limited/VBN
to/TO
the/DT
interrogation/NN
of/IN
features/NNS
on/IN
tumor-associated/JJ
factors/NNS
,/,
including/VBG
tumoral/JJ
somatic/JJ
mutation/NN
burden/NN
,/,
neoantigen/NN
load/NN
,/,
and/CC
PD-L1/NN
expression/NN
./.
====================
Recently/RB
,/,
however/RB
,/,
scRNA-Seq/NN
has/VBZ
been/VBN
used/VBN
to/TO
interrogate/VB
immune-related/JJ
factors/NNS
in/IN
both/CC
tumor/NN
cells/NNS
and/CC
microenvironment/NN
./.
====================
In/IN
a/DT
series/NN
of/IN
studies/NNS
,/,
scRNA-Seq/NN
was/VBD
used/VBN
in/IN
combination/NN
with/IN
tumor/NN
spatial/JJ
heterogeneity/NN
analysis/NN
to/TO
profile/VB
the/DT
mechanisms/NNS
of/IN
cancer-associated/JJ
immunosuppression/NN
on/IN
tumor-infiltrating/JJ
T-cell/NN
dysfunction/NN
[/(
22/CD
,/,
23/CD
]/)
,/,
immunosuppressive/JJ
tumoral/JJ
T/NN
cells/NNS
[/(
23/CD
]/)
,/,
and/CC
macrophages/NNS
[/(
24/CD
]/)
./.
====================
An/DT
analysis/NN
of/IN
melanomas/NNS
via/IN
scRNA-Seq/NN
revealed/VBD
spatial/JJ
and/CC
functional/JJ
heterogeneity/NN
in/IN
both/DT
the/DT
tumor/NN
and/CC
T/NN
cells/NNS
and/CC
further/RB
demonstrated/VBD
the/DT
range/NN
of/IN
T-cell/NN
activation/NN
,/,
clonal/JJ
expansion/NN
,/,
and/CC
exhaustion/NN
programs/NNS
within/IN
the/DT
tumor/NN
[/(
6/CD
]/)
./.
====================
Another/DT
study/NN
used/VBD
scRNA-Seq/NN
to/TO
determine/VB
the/DT
immune/JJ
landscape/NN
of/IN
melanoma/NN
patients/NNS
treated/VBN
with/IN
checkpoint/NN
inhibitors/NNS
and/CC
identified/VBD
two/CD
major/JJ
cell/NN
states/NNS
./.
====================
One/CD
state/NN
was/VBD
similar/JJ
to/TO
that/DT
of/IN
stem-cell-like/JJ
memory/NN
CD8/NN
T/NN
cells/NNS
and/CC
was/VBD
predominantly/RB
found/VBN
in/IN
tumors/NNS
that/DT
responded/VBD
to/TO
treatment/NN
,/,
whereas/IN
the/DT
other/JJ
state/NN
was/VBD
similar/JJ
to/TO
dysfunctional/JJ
or/CC
exhausted/VBD
T/NN
cells/NNS
and/CC
was/VBD
commonly/RB
seen/VBN
in/IN
resistant/JJ
tumors/NNS
[/(
25/CD
]/)
./.
====================
In/IN
a/DT
further/JJ
study/NN
,/,
scRNA-Seq/NN
was/VBD
applied/VBN
to/TO
map/VB
out/RP
a/DT
high-resolution/JJ
landscape/NN
of/IN
immunotherapyresistant/JJ
melanoma/NN
and/CC
subsequently/RB
discovered/VBN
a/DT
gene/NN
expression/NN
program/NN
that/DT
correlated/VBD
with/IN
reduced/VBN
tumor/NN
infiltrating/VBG
T/NN
cells/NNS
./.
====================
This/DT
study/NN
provided/VBD
a/DT
potential/JJ
approach/NN
to/TO
predict/VB
resistance/NN
to/TO
immunotherapy/NN
before/IN
treatment/NN
begins/VBZ
,/,
thereby/RB
providing/VBG
a/DT
potential/JJ
target/NN
as/IN
a/DT
means/NN
to/TO
delay/VB
or/CC
counter/NN
resistance/NN
[/(
26/CD
]/)
./.
====================
The/DT
discrepancy/NN
between/IN
mRNA/NN
and/CC
protein/NN
abundance/NN
has/VBZ
been/VBN
frequently/RB
reported/VBN
and/CC
even/RB
more/RBR
discordant/JJ
in/IN
the/DT
heterogenous/JJ
tissue/NN
of/IN
a/DT
tumor/NN
./.
====================
Although/IN
proteomic/JJ
studies/NNS
provide/VBP
accurate/JJ
information/NN
on/IN
the/DT
final/JJ
layer/NN
of/IN
intratumoral/JJ
heterogeneity/NN
,/,
single-cell/JJ
proteomics/NNS
has/VBZ
proven/VBN
to/TO
be/VB
more/RBR
challenging/JJ
than/IN
other/JJ
single-cell/JJ
genomic/JJ
sequencing/NN
methods/NNS
since/IN
there/EX
is/VBZ
currently/RB
no/DT
approach/NN
to/TO
amplify/VB
the/DT
initial/JJ
amount/NN
of/IN
protein/NN
./.
====================
Instead/RB
,/,
efforts/NNS
have/VBP
been/VBN
focused/VBN
on/IN
developing/VBG
methods/NNS
to/TO
more/RBR
sensitively/RB
detect/VB
small/JJ
amounts/NNS
of/IN
protein/NN
./.
====================
Single-cell/JJ
mass-cytometry/NN
(/(
also/RB
known/VBN
as/IN
CyTOF/NN
)/)
was/VBD
introduced/VBN
to/TO
tackle/JJ
this/DT
issue/NN
with/IN
the/DT
use/NN
of/IN
antibody/NN
conjugation/NN
in/IN
combination/NN
with/IN
MS/NN
in/IN
order/NN
to/TO
determine/VB
functional/JJ
properties/NNS
of/IN
cells/NNS
./.
====================
In/IN
a/DT
recent/JJ
study/NN
,/,
this/DT
single-cell/JJ
proteomic/JJ
method/NN
was/VBD
applied/VBN
to/TO
characterize/VB
the/DT
functional/JJ
states/NNS
of/IN
immune/JJ
cells/NNS
in/IN
melanoma/NN
patients/NNS
before/IN
and/CC
after/IN
antiâ€“PD-1/JJ
immunotherapy/NN
and/CC
found/VBD
that/IN
the/DT
frequency/NN
of/IN
CD14+/JJ
CD16âˆ’/JJ
HLA-DRhi/NNP
monocytes/NNS
in/IN
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
could/MD
be/VB
used/VBN
as/IN
a/DT
biomarker/NN
to/TO
discriminate/VB
responders/NNS
from/IN
nonresponders/NNS
[/(
27/CD
]/)
./.
====================
Single-cell/JJ
sequencing/NN
technologies/NNS
already/RB
have/VBP
led/VBN
to/TO
many/JJ
discoveries/NNS
in/IN
the/DT
field/NN
of/IN
cancer/NN
immunology/NN
and/CC
proven/VBN
it/PRP
can/MD
provide/VB
further/JJ
insight/NN
into/IN
our/PRP$
understanding/NN
of/IN
intratumor/JJ
heterogeneity/NN
,/,
immunoediting/VBG
,/,
and/CC
immunogenicity/NN
that/DT
are/VBP
difficult/JJ
to/TO
resolve/VB
from/IN
bulk/NN
sequencing/NN
./.
====================
Nevertheless/RB
,/,
many/JJ
dynamic/JJ
tumor/NN
processes/NNS
remain/VBP
poorly/RB
understood/VBN
./.
====================
With/IN
the/DT
continual/JJ
advances/NNS
in/IN
single-cell/JJ
methods/NNS
at/IN
an/DT
ever/RB
more/RBR
affordable/JJ
cost/RB
,/,
the/DT
repertoire/NN
of/IN
new/JJ
data/NNS
across/IN
additional/JJ
tumor/NN
types/NNS
and/CC
at/IN
unprecedented/JJ
sample/JJ
size/NN
will/MD
aid/VB
in/IN
capturing/VBG
individual/JJ
cell/NN
states/NNS
at/IN
the/DT
transcriptional/JJ
,/,
regulatory/JJ
,/,
and/CC
translational/JJ
layers/NNS
./.
====================
In/IN
combination/NN
with/IN
functional/JJ
work/NN
,/,
these/DT
mechanistic/JJ
insights/NNS
can/MD
be/VB
used/VBN
to/TO
identify/VB
prognostic/JJ
biomarkers/NNS
,/,
monitor/NN
circulating/VBG
tumor/NN
cells/NNS
,/,
map/VBP
rare/JJ
cell/NN
population/NN
,/,
estimate/VBP
and/CC
stratify/JJ
tumor/NN
and/CC
tumor/NN
microenvironment/NN
heterogeneity/NN
,/,
and/CC
,/,
finally/RB
,/,
be/VB
used/VBN
to/TO
identify/VB
therapy/NN
resistance/NN
mechanisms/NNS
./.
====================
Ultimately/RB
,/,
these/DT
approaches/NNS
will/MD
guide/NN
the/DT
way/NN
to/TO
detection/NN
of/IN
single-cell/JJ
signatures/NNS
in/IN
cancer/NN
,/,
precisely/RB
manipulate/VBP
immunity/NN
with/IN
therapy/NN
and/CC
vaccination/NN
to/TO
overcome/VB
immune/JJ
suppression/NN
,/,
revitalize/VBP
immune/JJ
surveillance/NN
,/,
and/CC
stabilize/VBP
or/CC
hopefully/RB
revert/VB
the/DT
tumor/NN
phenotype/NN
in/IN
cancer/NN
patients/NNS
./.
====================
Multi-omics/NNS
methods/NNS
====================
